Anzeige
Mehr »
Login
Samstag, 25.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Achtung! Ist das die Krypto-Aktie des Jahres 2024 mit 700% Potential?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14NHV | ISIN: BE0974280126 | Ticker-Symbol: BT1
Frankfurt
24.05.24
08:03 Uhr
0,015 Euro
+0,005
+41,28 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOSENIC SA Chart 1 Jahr
5-Tage-Chart
BIOSENIC SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,0190,03812:55

Aktuelle News zur BIOSENIC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrBioSenic provides First Quarter 2024 Business Update267PRESS RELEASE - REGULATED INFORMATION Mont-Saint-Guibert, Belgium, May 24, 2024, 17.00am CET - BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune...
► Artikel lesen
30.04.BioSenic S.A.: Information on the total number of voting rights and shares1
26.04.BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles1
24.04.BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 20232
18.04.BioSenic S.A.: Transparency notifications received from François Rieger2
17.04.XFRA BT1: WIEDERAUFNAHME/RESUMPTION115FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
12.04.BioSenic provides further information on its restructuring plan313PRESS RELEASE - PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, 12 April 2024, 12:00 CET - BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious...
► Artikel lesen
11.04.XFRA BT1: AUSSETZUNG/SUSPENSION77DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOSENIC S.A. BT1...
► Artikel lesen
29.03.BioSenic S.A.: Information on the total number of voting rights and shares3
20.03.BioSenic presents successful preclinical data on its ATO medication for controlling key symptoms at the 2024 Systemic Sclerosis World Congress122PRESS RELEASE Preclinical data in a transgenic mouse model shows beneficial effects on various clinical symptoms analogous to those observed in human systemic sclerosis.Findings may further support...
► Artikel lesen
12.03.BioSenic releases details of optimized administration approach ahead of planned Phase 3 trial of OATO for chronic graft-versus-host disease165INSIDE INFORMATION New data builds on earlier findings from a post-hoc Phase 2 analysis that helped reposition BioSenic's oral arsenic trioxide (OATO) program for pivotal trials.Data to be submitted...
► Artikel lesen
29.02.BioSenic S.A.: Information on the total number of voting rights and shares4
06.02.XFRA BT1: WIEDERAUFNAHME/RESUMPTION276FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
02.02.BioSenic raises €500,000 in private placement of new shares with established new investors475PRESS RELEASE - REGULATED INFORMATION NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA...
► Artikel lesen
02.02.XFRA BT1: AUSSETZUNG/SUSPENSION307DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOSENIC S.A. BT1...
► Artikel lesen
31.01.BioSenic provides support to forthcoming European conference on graft-versus-host disease1
30.01.BioSenic patent granted in Canada for broader protection of ATO therapeutic platform274PRESS RELEASE - INSIDE INFORMATION BioSenic patent granted in Canada for broader protection of its ATO therapeutic platform Composition-of-matter patent covers the therapeutic use of arsenic salts...
► Artikel lesen
25.01.BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress171PRESS RELEASE BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress Using a recently published approach to stratify patients with knee...
► Artikel lesen
23.01.BioSenic files for additional patent protection following new clinical evidence of efficacy for JTA-004 in osteoarthritis291PRESS RELEASE - INSIDE INFORMATION Following a post-hoc analysis of a Phase 3 trial demonstrating pain relief in patients with severe knee osteoarthritis, Biosenic applied for an international...
► Artikel lesen
16.01.BioSenic and Phebra switch up terms of licensing agreement2
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1